Orgenesis Stock Price

-0.04 (-0.72%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Orgenesis Inc ORGS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.04 -0.72% 5.53 20:00:00
Open Price Low Price High Price Close Price Prev Close
5.63 5.29 5.63 5.47 5.57
Bid Price Ask Price Spread News
5.26 5.59 0.33 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,554 105,518 $ 5.48 $ 578,603 811,274 4.14 - 8.30
Last Trade Time Type Quantity Stock Price Currency
19:01:13 1 $ 5.59 USD

Orgenesis Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 122.18M 22.09M 12.75M $ 7.65M $ 4.50M -1.62 27.16
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

Orgenesis News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ORGS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week5.115.855.005.36216,0120.428.22%
1 Month4.485.854.425.05178,5401.0523.44%
3 Months7.,216-1.53-21.67%
6 Months4.498.304.145.67309,9961.0423.16%
1 Year7.308.304.145.71192,668-1.77-24.25%
3 Years8.8512.002.355.6498,779-3.32-37.51%
5 Years9.4516.802.355.8694,971-3.92-41.48%

Orgenesis Description

Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210612 13:42:34